Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide effects on physical function in older adults
NCT05786521Phase 4Completed
- Sponsor
- UT Health San Antonio
- Start
- Apr 2023
- Primary completion
- May 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of semaglutide in obesity, type 2 diabetes mellitus (T2DM) and prediabetes (2 arms), sponsored by UT Health San Antonio. Primary endpoint: Lean Body Mass Change at 20 weeks. Started Apr 2023; status: completed.
02
Drugs
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)prediabetes
Beyond the preview
Go deeper on NCT05786521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05786521.